wellrank.ai
D'.M. logo

D'.M.

First cited by AI Jun 30, 2026
dmv.org

Surfaced organically in AI answers about ozempic. Not yet profiled.

D'.M. is losing the AEO war.

Not cited in a single tracked AI answer since Jul 4, 2026, down from a peak of 2% visibility in ozempic on Jun 30, 2026. This page stays public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

Ozempic, daily share of AI answers mentioning D'.M., through Jul 6, 2026.

0.0%

Last cited Jul 4, 2026 · peak 2% on Jun 30

By engine

Where D'.M. is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 1 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning D'.M.

PerplexityJun 30, 2026, 13:26 UTC
Ozempic vs Wegovy for weight loss: which do online clinics prescribe more easily?

Wegovy is prescribed more easily by online clinics for weight loss because it is the only medication FDA-approved specifically for chronic weight management, whereas Ozempic is approved only for type 2 diabetes and its use for weight loss is considered off-label and generally advised against due to supply constraints [1][3][6]. Key Reasons Online Clinics Prefer Wegovy for Weight Loss: Factor Wegovy Ozempic FDA Approval Approved for chronic weight management in adults with obesity (BMI ≥30) or weight-related conditions (BMI ≥27) [3][6] Approved only for type 2 diabetes; weight loss is a secondary effect (8–14%) [1][3][7] Prescribing Guidelines Clinics can prescribe it directly for weight loss without needing diabetes documentation [2][6] Using it for weight loss is off-label; many clinics advise against it due to supply constraints and ethical concerns [1][5][7] Clinical Trial Results Demonstrates 15–18% average weight loss over 68 weeks [2][3] Demonstrates 12–14% average weight loss [2][3] Insurance Coverage Covered when appropriate documentation for obesity is provided [3] Typically covered only with documentation for Type 2 diabetes [3] Important Considerations: Cost: Both medications are expensive without insurance, with out-of-pocket costs ranging from $650 to $1,500 per month [3]. In the UK, Wegovy starts around £89–£119 for lower doses, while Ozempic ranges £130–£250 [1]. Supply Constraints: Ozempic faces significant global shortages, making it harder for clinics to prescribe for non-diabetic purposes [1][5]. Medical Supervision: Switching between the two or using either requires clinical supervision [1][9]. Recommendation: If your primary goal is weight loss, choose Wegovy and seek online clinics that specialize in obesity management (e.g., D'.M., Calibrate, or Ro). These clinics are more likely to approve Wegovy quickly because it aligns with their covered condition. Avoid clinics that prescribe Ozempic for weight loss unless you have a documented diagnosis of type 2 diabetes, as this is not the standard or recommended practice [1][5][7].

Mentioned in position 1 of 3

Read full answer with sources →

Competitive Landscape

D'.M. vs the brands AI recommends alongside it

The real competitive set in Ozempic: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
D'.M. logo
D'.M.This brand
0.0%
Calibrate logo
Calibrate

1 shared answers

#7
25.0%
Ro logo
Ro

1 shared answers

#1
53.3%

Email me when overtakes D'.M.

One email the day the ranks flip. Nothing else.

Sources cited around D'.M.

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track D'.M. weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at D'.M.? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.